Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephanie Mehlis

Dermatology Skokie, IL Medical Doctor

NPI 1770634131 CMS profile 306923

9933 Woods Dr, 2Nd Floor - Dermatology, Skokie, IL 60077

Open in the dashboard

General payments

$144,766

208 records reported · program years 2019–2025

Research payments

$13,044

Paid to them · 16 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,282,509 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Stephanie Mehlis of Skokie, IL is reported in the CMS Open Payments database as having received $144,766 across 208 general payments and $13,044 in research payments paid to them. Separately, studies naming them as principal investigator received $6,282,509 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,396 21
2024 General $26,149 27
2024 Research $7,474 3
2023 General $15,231 33
2023 Research $2,977 8
2022 General $32,953 44
2022 Research $2,593 5
2021 General $10,389 10
2020 General $3,851 23
2019 General $33,796 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Mehlis
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Stephanie Mehlis were reported at $22,396. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Stephanie Mehlis Dermatology median Middle half National median
2019 $33,796 $454 $129–$1,240 $163
2020 $3,851 $235 $81–$756 $114
2021 $10,389 $377 $108–$1,108 $132
2022 $32,953 $514 $143–$1,391 $149
2023 $15,231 $607 $159–$1,674 $160
2024 $26,149 $751 $204–$1,903 $164
2025 $22,396 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $64,695 64 payments
  2. Janssen Scientific Affairs, LLC $27,833 31 payments
  3. AbbVie, Inc. $19,892 32 payments
  4. Novartis Pharmaceuticals Corporation $13,414 19 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $5,215 2 payments
  6. Pfizer Inc. $3,850 18 payments
  7. E.R. Squibb & Sons, L.L.C. $3,038 1 payment
  8. UCB, Inc. $2,418 3 payments
  9. LEO Pharma Inc. $2,234 3 payments
  10. UCB Biosciences Inc. $1,758 14 payments
  11. Other $419 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $91,352 32 payments
  2. Consulting Fee $36,321 11 payments
  3. Travel and Lodging $11,175 41 payments
  4. Food and Beverage $5,560 117 payments
  5. Education $358 7 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $92,466 87 payments
  2. SKYRIZI Immunology $19,652 22 payments
  3. COSENTYX $6,669 9 payments
  4. SPEVIGO $5,215 2 payments
  5. SOTYKTU $3,038 1 payment
  6. ENSTILAR $2,214 2 payments
  7. Bimekizumab $879 7 payments
  8. Otezla $173 14 payments
  9. SKYRIZI Immunology $139 6 payments
  10. RINVOQ $132 5 payments
  11. Other $657 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $6,496 6 payments
  2. Pfizer Inc. $5,740 5 payments
  3. F. Hoffmann-La Roche AG $659 1 payment
  4. AbbVie, Inc. $148 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

967

Median for Dermatology: 534

Drug cost

$1,890,629

Median for Dermatology: $67,151

Branded share of claims

23%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 17 $429,947
Stelara Ustekinumab Brand 19 $413,252
Cosentyx Sensoready (2 Pens) Secukinumab Brand 44 $390,746
Skyrizi Pen Risankizumab-Rzaa Brand 18 $372,049
Taltz Autoinjector Ixekizumab Brand 11 $106,466
Humira(Cf) Adalimumab Brand 13 $90,543
Dupixent Syringe Dupilumab Brand 14 $54,614
Calcipotriene Generic 26 $7,261
Pimecrolimus Generic 16 $4,904
Clobetasol Propionate Generic 77 $3,803

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$69,215

Medicare's payments for the services billed

Medicare patients

651

Average age 76

Services billed

1,915

421 women, 230 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 47%
Osteoporosis 24%
Diabetes 21%
Ischemic heart disease 19%
Cancer 18%
Chronic kidney disease 17%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $20,847
$20,847 — —
SPEVIGO
  • Boehringer Ingelheim Pharmaceuticals, Inc. $5,215
$5,215 — —
DUPIXENT
  • GENZYME CORPORATION $22
$22 14 —
ADBRY
  • LEO Pharma Inc. $20
$20 — —
CIBINQO
  • PFIZER INC. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record